Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNE | Q9Y223 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LANCL2 | Q9NS86 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SCD | O00767 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088489 | 0.88 | GNE (0.53) | GNESMN1; SMN2MAPK1USP2DPP4 | |
| SCHEMBL3088488 | 0.86 | SMN1; SMN2 (0.54) | GNESMN1; SMN2MAPK1USP2DPP4 | |
| SCHEMBL3086677 | 0.83 | HRH4 (0.50) | GNESMN1; SMN2MAPK1USP2DPP4 | |
| SCHEMBL1579475 | 0.81 | GNE (0.55) | GNESMN1; SMN2MAPK1USP2L3MBTL1 | |
| SCHEMBL13450575 | 0.80 | HSD11B1 (0.60) | GNESMN1; SMN2MAPK1USP2DPP4 | |
| SCHEMBL12120506 | 0.80 | DPP4 (0.55) | GNESMN1; SMN2MAPK1USP2DPP4 | |
| SCHEMBL3081021 | 0.79 | POLB (0.51) | GNESMN1; SMN2MAPK1USP2DPP4 | |
| SCHEMBL13148292 | 0.78 | KMT2A (0.56) | SMN1; SMN2LMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL1578831 | 0.78 | L3MBTL1 (0.46) | GNESMN1; SMN2MAPK1USP2DPP4 | |
| SCHEMBL22491434 | 0.76 | FNTA (0.44) | GNESMN1; SMN2MAPK1USP2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | claimed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | claimed |
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2150532-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | Evotec AG (DE) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008122787-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | EVOTEC AG (DE) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234377-A1 | PIPERAZINE COMPOUNDS FOR THE INHIBITION OF HAEMATOPOIETIC PROSTAGLANDIN D SYNTHASE | HPGDS, PTGDR, PTGIS | GNE 1078/4885SMN1; SMN2 1866/4885MAPK1 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.